236 related articles for article (PubMed ID: 32771306)
1. The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians.
Subbiah V; Solit DB; Chan TA; Kurzrock R
Ann Oncol; 2020 Sep; 31(9):1115-1118. PubMed ID: 32771306
[No Abstract] [Full Text] [Related]
2. The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No.
Prasad V; Addeo A
Ann Oncol; 2020 Sep; 31(9):1112-1114. PubMed ID: 32771305
[No Abstract] [Full Text] [Related]
3. FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors.
Marcus L; Fashoyin-Aje LA; Donoghue M; Yuan M; Rodriguez L; Gallagher PS; Philip R; Ghosh S; Theoret MR; Beaver JA; Pazdur R; Lemery SJ
Clin Cancer Res; 2021 Sep; 27(17):4685-4689. PubMed ID: 34083238
[TBL] [Abstract][Full Text] [Related]
4. Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence.
Passaro A; Stenzinger A; Peters S
Cancer Cell; 2020 Nov; 38(5):624-625. PubMed ID: 33171127
[TBL] [Abstract][Full Text] [Related]
5. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
Ott PA; Bang YJ; Piha-Paul SA; Razak ARA; Bennouna J; Soria JC; Rugo HS; Cohen RB; O'Neil BH; Mehnert JM; Lopez J; Doi T; van Brummelen EMJ; Cristescu R; Yang P; Emancipator K; Stein K; Ayers M; Joe AK; Lunceford JK
J Clin Oncol; 2019 Feb; 37(4):318-327. PubMed ID: 30557521
[TBL] [Abstract][Full Text] [Related]
6. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Marabelle A; Fakih M; Lopez J; Shah M; Shapira-Frommer R; Nakagawa K; Chung HC; Kindler HL; Lopez-Martin JA; Miller WH; Italiano A; Kao S; Piha-Paul SA; Delord JP; McWilliams RR; Fabrizio DA; Aurora-Garg D; Xu L; Jin F; Norwood K; Bang YJ
Lancet Oncol; 2020 Oct; 21(10):1353-1365. PubMed ID: 32919526
[TBL] [Abstract][Full Text] [Related]
7. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors.
Marcus L; Lemery SJ; Keegan P; Pazdur R
Clin Cancer Res; 2019 Jul; 25(13):3753-3758. PubMed ID: 30787022
[TBL] [Abstract][Full Text] [Related]
8. First Tissue-Agnostic Drug Approval Issued.
Cancer Discov; 2017 Jul; 7(7):656. PubMed ID: 28583911
[TBL] [Abstract][Full Text] [Related]
9. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.
Boyiadzis MM; Kirkwood JM; Marshall JL; Pritchard CC; Azad NS; Gulley JL
J Immunother Cancer; 2018 May; 6(1):35. PubMed ID: 29754585
[TBL] [Abstract][Full Text] [Related]
10. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
[TBL] [Abstract][Full Text] [Related]
11. FDA Accelerated Approval of Pembrolizumab for Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma.
Bradford D; Demko S; Jin S; Mishra-Kalyani P; Beckles AR; Goldberg KB; Lemery S; Ward A; Keegan P; Pazdur R
Oncologist; 2020 Jul; 25(7):e1077-e1082. PubMed ID: 32272501
[TBL] [Abstract][Full Text] [Related]
12. Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers.
Prasad V; Kaestner V; Mailankody S
JAMA Oncol; 2018 Feb; 4(2):157-158. PubMed ID: 29285544
[No Abstract] [Full Text] [Related]
13. FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.
Pai-Scherf L; Blumenthal GM; Li H; Subramaniam S; Mishra-Kalyani PS; He K; Zhao H; Yu J; Paciga M; Goldberg KB; McKee AE; Keegan P; Pazdur R
Oncologist; 2017 Nov; 22(11):1392-1399. PubMed ID: 28835513
[TBL] [Abstract][Full Text] [Related]
14. Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.
Fabrizio D; Cristescu R; Albacker L; Snyder A; Ward A; Lunceford J; Aurora-Garg D; Jin F; Hopkins J; Rubin E; Hegde P
Ann Oncol; 2021 Sep; 32(9):1193-1194. PubMed ID: 34082018
[No Abstract] [Full Text] [Related]
15. Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy.
Goodman AM; Sokol ES; Frampton GM; Lippman SM; Kurzrock R
Cancer Immunol Res; 2019 Oct; 7(10):1570-1573. PubMed ID: 31405947
[TBL] [Abstract][Full Text] [Related]
16. FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
Fashoyin-Aje L; Donoghue M; Chen H; He K; Veeraraghavan J; Goldberg KB; Keegan P; McKee AE; Pazdur R
Oncologist; 2019 Jan; 24(1):103-109. PubMed ID: 30120163
[TBL] [Abstract][Full Text] [Related]
17. Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al.
McGrail DJ; Pilié PG; Rashid NU; Voorwerk L; Slagter M; Kok M; Jonasch E; Khasraw M; Heimberger AB; Ueno NT; Ferrarotto R; Chang JT; Lin SY
Ann Oncol; 2021 Sep; 32(9):1194-1197. PubMed ID: 34166757
[No Abstract] [Full Text] [Related]
18. When biomarkers define a drug indication.
Jørgensen JT
Expert Rev Mol Diagn; 2018 Apr; 18(4):315-317. PubMed ID: 29333885
[No Abstract] [Full Text] [Related]
19. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
[TBL] [Abstract][Full Text] [Related]
20. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
Suzman DL; Agrawal S; Ning YM; Maher VE; Fernandes LL; Karuri S; Tang S; Sridhara R; Schroeder J; Goldberg KB; Ibrahim A; McKee AE; Pazdur R; Beaver JA
Oncologist; 2019 Apr; 24(4):563-569. PubMed ID: 30541754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
